Framingham, Mass., April 27, 2007-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the first quarter 2007 will be released on Thursday, May 3, 2007 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on May 3 starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows:
Live Call - In the United States, dial 1-866-362-4820Outside the United States, dial 1-617-597-5345
Reference call ID: when prompted 63342680
Audio Archive - In the United States, dial 1-888-286-8010
Outside the United States, dial 1-617-801-6888
Reference call ID: when prompted 75806146
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until May 10, 2007. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About GTC Biotherapeutics
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATrynŽ, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATrynŽ is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATrynŽ, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.
GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com. CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare
Francesca DeVellis (investors)
(617) 577-8110
Copyright 2006 GTC Biotherapeutics, All Rights Reserved